US FDA Commissioner Praises India Ahead of BioPharma Summit
US FDA Commissioner's Address
Dr. Robert Califf, Commissioner of the US Food and Drug Administration (FDA), underscores India’s pivotal position in the medical product landscape, balancing unique opportunities with significant responsibilities. His remarks precede the India-US BioPharma & Healthcare Summit, slated to convene in Boston later this week, organized by the USA-India Chamber of Commerce.
Insights from Recent India Visit
Scheduled as a keynote speaker, Dr. Califf aims to delve into insights gleaned from his recent visit to India, emphasizing collaborative efforts to develop and ensure global access to essential medical products. Addressing concerns flagged by FDA investigators regarding manufacturing quality and clinical trial practices in India, he stresses the imperative of upholding stringent standards in both realms.
Distinguished Summit Speakers
The summit boasts a distinguished lineup of speakers, including Biogen CEO Chris Viehbacher and representatives from Takeda, Novo Nordisk, Bristol Myers Squibb, Stanford University, and Harvard Medical School. Indian pharmaceutical titans like Dilip Shanghvi of Sun Pharma and Hari Bhartia of the Jubilant Bhartia Group will also grace the event.
Â
India's Innovation and Manufacturing
Karun Rishi, President of the USA India Chamber of Commerce, lauds India’s innovation prowess and skilled workforce, spotlighting its capacity to scale up manufacturing while maintaining quality benchmarks. This underscores India’s pivotal role in global medication supply and addresses critical issues within the BioPharma supply chain and health security.
Recognition for Industry Contributions
Dr. Andrew Plump of Takeda is set to receive the “Distinguished Service Award” for his endeavors in fostering industry-academia collaboration and advancing biomedical research and development.
Global Collaboration for Medical Innovation
The summit underscores the imperative of global partnerships to propel medical innovation, benefiting India and the global community alike. Such collaborations are deemed essential for bolstering healthcare delivery and effectively combating global health challenges. Through sustained engagement with international BioPharma leaders and supportive governmental policies, India continues to cement its position as a strategic ally in the BioPharma sector, demonstrating resilience amid prevailing global adversities.
Source: Inputs from various media Sources
